GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of survodutide vs glucagon — genuinely asking which matters more — 58 comments in the full submission. View in context.
853
c/survodutide·submitted 8 months ago by u/patient_labslip_log

survodutide vs glucagon — genuinely asking which matters more

Questionbranch of 7 comments

Confession thread, sort of. I went from 15mg to 7.5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 13 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have early…

Read the full submission and all 58 comments →

This branch

7 comments, started 8 months ago
u/joaquin_ivaturi20 points·8 months ago

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

replysharereportpermalink
u/draw_up_dizzy7 points·8 months ago·edited

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/liv_vukovic26 points·8 months ago

Inter-lab variance on this kind of assay is routinely 1–2 points.

Disagree on that part. 97.4% and 97.6% on the same vial is normal.

replysharereportpermalink
u/trialwatch_theoMOD12 points·8 months ago

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

replysharereportpermalink
u/thermal_mass_tom18 points·8 months ago

Hepatic fat or MASH or what?

replysharereportpermalink
u/old_account_202312 points·8 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/cold_chromatogram_only8 points·8 months ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →